SCHEMBL5527062

SCHEMBL5527062

[CH]1Nc2cccc3c2C1CCC3

nearest known ligand 0.47

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.33
TSHR P16473 1/20 0.32
IDO1 P14902 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11256984 0.71 PLAU (0.36) MAPT
SCHEMBL137922 0.68 TSHR (0.36) TSHRIDO1
SCHEMBL4501455 0.68 OPRL1 (0.35)
SCHEMBL829452 0.68 TSHR (0.43) TSHR
SCHEMBL4494937 0.67 HCRTR1 (0.35)
SCHEMBL4510414 0.67 OPRM1 (0.35)
SCHEMBL4186361 0.67 MAPT (0.43) MAPT
SCHEMBL22699873 0.66 MAPT (0.35) MAPT
SCHEMBL10684858 0.66 ATM (0.47) TSHRIDO1
SCHEMBL11250932 0.65 MAPT (0.34) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070203140-A1 N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION 2007-08-30 US claimed
WO-2007095050-A2 N-HYDROXYGUANIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2007-08-23 WO claimed
US-20070203140-A1 N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION 2007-08-30 US disclosed
WO-2007095050-A2 N-HYDROXYGUANIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203140-A1 N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase IDO1, IDO2, HNMT MAPT 2160/4885TSHR 3269/4885IDO1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.